Short-Acting Oral Nifedipine versus Intravenous Labetalol for the Control of Severe Hypertension in the Postpartum Period: A Retrospective Cohort Study.

IF 1.5 4区 医学 Q3 OBSTETRICS & GYNECOLOGY
American journal of perinatology Pub Date : 2025-04-01 Epub Date: 2024-10-30 DOI:10.1055/a-2422-9768
Whitney A Booker, Shai Bejerano, Anna Frappaolo, Eliza C Miller, Natalie A Bello
{"title":"Short-Acting Oral Nifedipine versus Intravenous Labetalol for the Control of Severe Hypertension in the Postpartum Period: A Retrospective Cohort Study.","authors":"Whitney A Booker, Shai Bejerano, Anna Frappaolo, Eliza C Miller, Natalie A Bello","doi":"10.1055/a-2422-9768","DOIUrl":null,"url":null,"abstract":"<p><p>This study aimed to compare the effectiveness of oral short-acting (SA) nifedipine with intravenous (IV) labetalol for the treatment of postpartum (PP) severe hypertension.We conducted a retrospective cohort study of women who delivered at a tertiary care facility between January and December 2018, had not previously received antihypertensive medication, and required treatment for PP severe hypertension defined as systolic blood pressure (SBP) ≥ 160 mm Hg and/or diastolic blood pressure (DBP) ≥110 mm Hg. Exposure groups were defined by the receipt of either oral SA nifedipine or IV labetalol. The primary outcome was time (minutes) to BP control (SBP < 160 mm Hg and DBP <110 mm Hg). Secondary outcomes included number of doses required to achieve BP control, crossover to the alternative medication, and recurrence of severe range BP after the achievement of BP control. <i>t</i>-Tests and Wilcoxon-Mann-Whitney tests were used to analyze continuous variables and chi-square tests or Fisher's exact tests were used to analyze categorical variables. Multivariable linear regression models were conducted for the primary outcome, controlling for potential confounders in a sequential fashion across three models. A Kaplan-Meier plot was also created.Of the 99 women included, 74 received oral SA nifedipine and 25 received IV labetalol. There was no significant difference in minutes to initial BP control between groups (30.5 minutes [interquartile range, IQR: 20.0-45.0] vs. 25.0 minutes [IQR: 14.0-50.0]; <i>p</i> = 0.82) or in the rate of recurrent severe BP. However, patients who received nifedipine required fewer doses to achieve control (<i>p</i> < 0.01) and did not require crossover (0 vs. 12%, <i>p</i> = 0.01).Both oral SA nifedipine and IV labetalol are effective options for treating PP severe hypertension. An initial choice of nifedipine was associated with a lower requirement for subsequent doses of medication and no need for crossover to an alternative antihypertensive medication. · Nifedipine and labetalol effectively treat PP severe HTN.. · Nifedipine requires fewer doses to treat PP severe HTN.. · Both have low recurrence rates of severe HTN..</p>","PeriodicalId":7584,"journal":{"name":"American journal of perinatology","volume":" ","pages":"806-812"},"PeriodicalIF":1.5000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of perinatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1055/a-2422-9768","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/30 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

This study aimed to compare the effectiveness of oral short-acting (SA) nifedipine with intravenous (IV) labetalol for the treatment of postpartum (PP) severe hypertension.We conducted a retrospective cohort study of women who delivered at a tertiary care facility between January and December 2018, had not previously received antihypertensive medication, and required treatment for PP severe hypertension defined as systolic blood pressure (SBP) ≥ 160 mm Hg and/or diastolic blood pressure (DBP) ≥110 mm Hg. Exposure groups were defined by the receipt of either oral SA nifedipine or IV labetalol. The primary outcome was time (minutes) to BP control (SBP < 160 mm Hg and DBP <110 mm Hg). Secondary outcomes included number of doses required to achieve BP control, crossover to the alternative medication, and recurrence of severe range BP after the achievement of BP control. t-Tests and Wilcoxon-Mann-Whitney tests were used to analyze continuous variables and chi-square tests or Fisher's exact tests were used to analyze categorical variables. Multivariable linear regression models were conducted for the primary outcome, controlling for potential confounders in a sequential fashion across three models. A Kaplan-Meier plot was also created.Of the 99 women included, 74 received oral SA nifedipine and 25 received IV labetalol. There was no significant difference in minutes to initial BP control between groups (30.5 minutes [interquartile range, IQR: 20.0-45.0] vs. 25.0 minutes [IQR: 14.0-50.0]; p = 0.82) or in the rate of recurrent severe BP. However, patients who received nifedipine required fewer doses to achieve control (p < 0.01) and did not require crossover (0 vs. 12%, p = 0.01).Both oral SA nifedipine and IV labetalol are effective options for treating PP severe hypertension. An initial choice of nifedipine was associated with a lower requirement for subsequent doses of medication and no need for crossover to an alternative antihypertensive medication. · Nifedipine and labetalol effectively treat PP severe HTN.. · Nifedipine requires fewer doses to treat PP severe HTN.. · Both have low recurrence rates of severe HTN..

控制产后严重高血压的短效口服硝苯地平与静脉注射拉贝洛尔:一项回顾性队列研究
研究目的本研究旨在比较口服短效(SA)硝苯地平与静脉注射(IV)拉贝洛尔治疗产后(PP)重度高血压的有效性:我们开展了一项回顾性队列研究,研究对象为2018年1月至12月期间在一家三级医疗机构分娩、之前未接受过降压药物治疗、需要治疗PP重度高血压(定义为收缩压(SBP)≥160 mm Hg和/或舒张压(DBP)≥110 mm Hg)的产妇。暴露组的定义是口服 SA 硝苯地平或静脉注射拉贝洛尔。主要结果是血压控制时间(分钟)(SBP t 检验和 Wilcoxon-Mann-Whitney 检验用于分析连续变量,秩方检验或费雪精确检验用于分析分类变量。对主要结果采用多变量线性回归模型,在三个模型中依次控制潜在的混杂因素。同时还绘制了卡普兰-梅耶曲线图:在纳入的 99 名妇女中,74 人接受了口服 SA 硝苯地平,25 人接受了静脉注射拉贝洛尔。两组患者的初始血压控制时间无明显差异(30.5 分钟 [四分位数间距:20.0-45.0] vs. 25.0 分钟 [四分位数间距:14.0-50.0];P = 0.82),复发严重血压的比率也无明显差异。然而,接受硝苯地平治疗的患者需要更少的剂量才能达到控制血压的目的(P = 0.01):结论:口服 SA 硝苯地平和静脉注射拉贝洛尔都是治疗 PP 重度高血压的有效选择。结论:口服SA硝苯地平和静脉注射拉贝洛尔都是治疗PP重度高血压的有效选择,最初选择硝苯地平可降低后续用药剂量的需求,且无需交叉使用其他降压药物:- 要点:硝苯地平和拉贝洛尔能有效治疗 PP 重度高血压。- 硝苯地平治疗 PP 重度高血压所需的剂量较少。- 两种药物的重度高血压复发率都很低。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
American journal of perinatology
American journal of perinatology 医学-妇产科学
CiteScore
5.90
自引率
0.00%
发文量
302
审稿时长
4-8 weeks
期刊介绍: The American Journal of Perinatology is an international, peer-reviewed, and indexed journal publishing 14 issues a year dealing with original research and topical reviews. It is the definitive forum for specialists in obstetrics, neonatology, perinatology, and maternal/fetal medicine, with emphasis on bridging the different fields. The focus is primarily on clinical and translational research, clinical and technical advances in diagnosis, monitoring, and treatment as well as evidence-based reviews. Topics of interest include epidemiology, diagnosis, prevention, and management of maternal, fetal, and neonatal diseases. Manuscripts on new technology, NICU set-ups, and nursing topics are published to provide a broad survey of important issues in this field. All articles undergo rigorous peer review, with web-based submission, expedited turn-around, and availability of electronic publication. The American Journal of Perinatology is accompanied by AJP Reports - an Open Access journal for case reports in neonatology and maternal/fetal medicine.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信